<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MEDROXYPROGESTERONE ACETATE</span><br/>(me-drox'ee-proe-jess'te-rone)<br/><span class="topboxtradename">Cycrin, </span><span class="topboxtradename">Depo-Provera, </span><span class="topboxtradename">Depo-subQ Provera 104, Provera<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">progestin</span><br/><b>Prototype: </b>Progesterone<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg, 5 mg, 10 mg tablets; 104 mg/0.65 mL, 150 mg/mL, 400 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic derivative of progesterone with prolonged, variable duration of action and androgenic and antiestrogenic activity.
         No deleterious effects on lipid metabolism.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Induces and maintains endometrium, preventing uterine bleeding; inhibits production of pituitary gonadotropin, preventing
         ovulation; and produces thick cervical mucus resistant to passage of sperm.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Dysfunctional uterine bleeding; secondary amenorrhea; parenteral form (Depo-Provera) used in adjunctive, palliative treatment
         of inoperable, recurrent, and metastatic endometrial or renal carcinoma; contraception; endometriosis-associated pain.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Obstructive sleep apnea.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of thromboembolic disorders; pregnancy (category X), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Asthma, seizure disorders, migraine, cardiac or kidney dysfunction, liver disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Secondary Amenorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 510 mg/d for 510 d beginning any time if endometrium is adequately estrogen primed (withdrawal bleeding occurs
               in 37 d after discontinuing therapy)<br/><br/><span class="indicationtitle">Abnormal Bleeding due to Hormonal Imbalance</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 510 mg/d for 510 d beginning on the assumed or calculated 16th or 21st day of menstrual cycle; if bleeding is
               controlled, administer 2 subsequent cycles<br/><br/><span class="indicationtitle">Carcinoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 4001000 mg/wk; continue at 400 mg/mo if improvement occurs and disease stabilizes<br/><br/><span class="indicationtitle">Contraceptive</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 100 mg q3mo<br/><br/><span class="indicationtitle">Sleep Apnea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20 mg t.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Oral drug may be given with food to minimize GI distress.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Administer IM deep into a large muscle.</li>
<li>Store both formulations at 15°30° C (59°86° F); protect from freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-life">Cerebral thrombosis or hemorrhage</span>, depression. <span class="typehead">CV:</span> Hypertension, pulmonary embolism, edema. <span class="typehead">GI:</span> Vomiting, nausea, cholestatic jaundice, abdominal cramps. <span class="typehead"> Urogenital:</span>
<span class="speceff-common">Breakthrough bleeding,</span> changes in menstrual flow, dysmenorrhea, vaginal candidiasis. <span class="typehead">Skin:</span> Angioneurotic edema. <span class="typehead">Body as a Whole:</span> Weight changes; <span class="speceff-common">breast tenderness,</span> enlargement or secretion. <span class="typehead">Musculoskeletal:</span> Loss of bone mineral density. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Aminoglutethimide</b> decreases serum concentrations of medroxyprogesterone; <span class="classification">barbiturates</span>, <b>carbamazepine,</b>
<b>oxcarbazepine,</b>
<b>phenytoin,</b>
<b>primidone,</b>
<b>rifampin,</b>
<b>modafinil,</b>
<b>rifabutin,</b>
<b>topiramate</b> can increase metabolism and decrease serum levels of medroxyprogesterone. <span class="typehead">Herbal:</span> intermenstrual bleeding and loss of contraceptive efficacy may occur with <b>St. John's wort.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 24 h PO, 3 wk IM. <span class="typehead"> Distribution:</span> &gt;90% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in feces. <span class="typehead">Half-Life:</span> 30 d PO, 50 d IM. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>See progesterone for numerous additional nursing implications.</li>
<li>Be aware that IM injection may be painful. Monitor sites for evidence of sterile abscess. A residual lump and discoloration
            of tissue may develop.
         </li>
<li>Monitor for S&amp;S of thrombophlebitis (see Appendix F).</li>
<li>
            							Note: Planned menstrual cycling with medroxyprogesterone may benefit the patient with a history of recurrent episodes of abnormal
            uterine bleeding.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that after repeated IM injections, infertility and amenorrhea may persist as long as 18 mo.</li>
<li>Learn breast self-examination.</li>
<li>Review package insert to ensure complete understanding of progestin therapy.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>